Author + information
- Received August 16, 2018
- Revision received October 1, 2018
- Accepted October 1, 2018
- Published online April 17, 2019.
- aCardiology Department, Wroclaw Medical University, Wroclaw, Poland
- bMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia
- cBaker Heart and Diabetes Institute, Melbourne, Australia
- ↵∗Address for correspondence:
Dr. Wojciech Kosmala; Cardiology Department, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
• ALVDD is associated with incident HF and decreased survival, with both cardiovascular and noncardiovascular factors contributing to the transition to overt disease.
• Abnormalities of diastolic function might be included in the definition of preclinical stage B HF to facilitate the identification of individuals at risk for the development of symptomatic HF.
• Imaging techniques, especially echocardiography, are necessary for the recognition of ALVDD, as well as further tracking of pathological changes and responses to treatment.
• Pre-emptive management strategies targeting cardiovascular and systemic comorbidities in patients with ALVDD may delay symptomatic progression and improve prognosis, and echocardiographic surveillance may aid to achieve the desired clinical benefits.
Asymptomatic left ventricular diastolic dysfunction (ALVDD) (diastolic abnormalities and normal ejection fraction in the absence of symptoms) is associated with incident heart failure (HF) and decreased survival. Abnormalities of diastolic function might therefore be included in the definition of stage B HF, which denotes individuals at risk for the development of HF. Imaging techniques, especially echocardiography, are necessary for the recognition of preclinical left ventricular (LV) diastolic disturbances, as well as further tracking of pathological changes and responses to treatment. The transition of ALVDD to symptomatic HF is underlain by multiple factors, including both cardiovascular and noncardiovascular determinants. The initiation of management strategies targeting cardiovascular and systemic comorbidities in patients identified as having ALVDD may delay symptomatic progression and improve prognosis.
- global longitudinal strain
- heart failure with preserved ejection fraction
- left ventricular diastolic dysfunction
- stage B heart failure
Dr. Kosmala has reported that he has no relationships relevant to the contents of this paper to disclose. Dr. Marwick has received research grant support from GE Medical Systems. Sherif Nagueh, MD, served as the Guest Editor for this paper.
- Received August 16, 2018.
- Revision received October 1, 2018.
- Accepted October 1, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.